Australian Clinical Labs

Rising Costs And Competition Will Squeeze Margins Yet Preserve Value

AnalystLowTarget

Not Invested

Consensus Narrative from 10 Analysts

Published

12 Jul 25

Updated

28 Aug 25

AnalystLowTarget's Fair Value

AU$2.90

1.7% undervalued

28 Aug

AU$2.85

-5.0%

13.5%

-5.0%

13.5%

Author's Valuation

AU$2.9

1.7% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

AU$2.9

1.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.21%

Healthcare Services revenue growth rate

0.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$41.49m

Earnings '28

15.27x

PE Ratio '28

AU$633.66m

Market Cap '28

AU$633.66m

Market Cap '28

181.12m

No. shares '28

AU$3.50

Share Price '28

AU$3.50 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$2.90

Fair Value '25